This announcement was flagged as important on the ASX. This is not noteworthy in way shape or form as far as I can tell. Whoever flagged this should be a bit more cautious.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%